Our model can be used for the prediction of the EBH affinity to different natural ligands and as a rationale for the design of small molecules to inhibit EB1 interactions that have a recognised contribution to human neoplastic diseases such as cancer (Abiatari et al., 2009; Liu et al., 2009). Here, MAPRE1 is linked to cancer.